Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,120 shares of the biopharmaceutical company's stock after purchasing an additional 1,306 shares during the quarter. Thrivent Financial for Lutherans' holdings in Regeneron Pharmaceuticals were worth $9,587,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of REGN. Claro Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 110.6% in the third quarter. Claro Advisors LLC now owns 478 shares of the biopharmaceutical company's stock valued at $502,000 after purchasing an additional 251 shares during the last quarter. Concord Asset Management LLC VA boosted its stake in shares of Regeneron Pharmaceuticals by 16.7% in the third quarter. Concord Asset Management LLC VA now owns 1,064 shares of the biopharmaceutical company's stock worth $1,119,000 after buying an additional 152 shares during the last quarter. Atlanta Consulting Group Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $534,000. Schear Investment Advisers LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $397,000. Finally, Natixis Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 0.3% in the third quarter. Natixis Advisors LLC now owns 117,002 shares of the biopharmaceutical company's stock valued at $122,997,000 after acquiring an additional 319 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Trading Down 0.9 %

REGN stock traded down $6.50 during trading on Friday, reaching $738.00. 1,029,423 shares of the stock were exchanged, compared to its average volume of 539,322. The business has a 50 day moving average price of $953.38 and a 200-day moving average price of $1,028.16. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $81.10 billion, a price-to-earnings ratio of 18.45, a P/E/G ratio of 2.81 and a beta of 0.15.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of analyst reports. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, October 22nd. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Oppenheimer dropped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. Finally, Truist Financial reduced their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.